Kathy Mulgrew

AstraZeneca (Netherlands) — Netherlands

Medicine · Health Sciences

18h-index2.3kcitations137works6.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(69), Cytokine Signaling Pathways and Interactions(34), CAR-T cell therapy research(31), Monoclonal and Polyclonal Antibodies Research(30), Lung Cancer Treatments and Mutations(25)

Publications137 total

Supplementary Figure S14 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Figure S1 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Figures S1-S3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
2023Open Access
Supplementary Table S6 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Figure S4 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Figure S1 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Figure S3 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Data from Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1<sup>+</sup> Activated T Cells
2023Open Access
MEDI5752FINALSupplementaryMaterial.docx from Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1<sup>+</sup> Activated T Cells
2023Open Access
Supplementary Figure S13 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
MEDI5752FINALSupplementaryMaterial.docx from Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1<sup>+</sup> Activated T Cells
2023Open Access
Figures S1-S3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
2023Open Access
Supplementary Figure S10 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Figure S4 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
2023Open Access
Supplementary Figure S2 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Tables 1-3 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
2023Open Access
Supplementary Table S1 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Supplementary Table S3 from Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional <i>STK11</i> Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown
2023Open Access
Figure S4 from Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein
2023Open Access
Data from Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1<sup>+</sup> Activated T Cells
2023Open Access
← Previouspage 2 of 7Next →

Frequent Co-authors

Scott A. Hammond(18), Raymond Rothstein(16), Michael D. Oberst(16), Philip Martin(14), Ronald Herbst(13), John Meekin(13), Nathan Standifer(11), Ricardo J. Miragaia(11), Kelly McGlinchey(10), Nabendu Pore(10), Maria Jure‐Kunkel(10), Yashaswi Shrestha(10), Rebecca Halpin(10), Ina Bisha(10), Theresa A. Proia(10), Ashok Gupta(10), Shaad E. Abdullah(10), Rajiv Raja(10), Melanie M. Frigault(10), Phillip A. Dennis(10)